Concepts (196)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Mammaplasty | 18 | 2022 | 780 | 2.810 |
Why?
|
| Abdominal Wall | 18 | 2023 | 184 | 2.470 |
Why?
|
| Hernia, Ventral | 15 | 2023 | 159 | 2.370 |
Why?
|
| Herniorrhaphy | 15 | 2023 | 169 | 1.840 |
Why?
|
| Surgical Mesh | 17 | 2023 | 209 | 1.660 |
Why?
|
| Acellular Dermis | 13 | 2021 | 103 | 1.590 |
Why?
|
| Surgical Flaps | 11 | 2020 | 927 | 1.270 |
Why?
|
| Free Tissue Flaps | 4 | 2020 | 372 | 1.130 |
Why?
|
| Postoperative Complications | 24 | 2021 | 5542 | 1.020 |
Why?
|
| Abdominal Muscles | 3 | 2023 | 68 | 1.000 |
Why?
|
| Mastectomy, Segmental | 8 | 2020 | 1026 | 0.760 |
Why?
|
| Breast Neoplasms | 18 | 2021 | 15694 | 0.760 |
Why?
|
| Surgical Wound Dehiscence | 4 | 2018 | 129 | 0.730 |
Why?
|
| Abdominal Wound Closure Techniques | 7 | 2016 | 40 | 0.700 |
Why?
|
| Superficial Back Muscles | 1 | 2019 | 18 | 0.690 |
Why?
|
| Mastectomy | 6 | 2020 | 1534 | 0.690 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 3 | 2019 | 674 | 0.650 |
Why?
|
| Fat Necrosis | 3 | 2022 | 63 | 0.610 |
Why?
|
| Microvessels | 1 | 2018 | 135 | 0.580 |
Why?
|
| Tissue and Organ Harvesting | 5 | 2021 | 148 | 0.560 |
Why?
|
| Thoracic Wall | 4 | 2020 | 183 | 0.560 |
Why?
|
| Skin Transplantation | 2 | 2013 | 173 | 0.520 |
Why?
|
| Ischemia | 1 | 2018 | 391 | 0.500 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2019 | 799 | 0.460 |
Why?
|
| Hernia, Abdominal | 3 | 2019 | 41 | 0.400 |
Why?
|
| Treatment Outcome | 33 | 2023 | 32848 | 0.390 |
Why?
|
| Retrospective Studies | 38 | 2023 | 37905 | 0.390 |
Why?
|
| Breast Implants | 4 | 2021 | 391 | 0.390 |
Why?
|
| Prostheses and Implants | 1 | 2013 | 295 | 0.390 |
Why?
|
| Follow-Up Studies | 20 | 2020 | 14889 | 0.380 |
Why?
|
| Abdominal Neoplasms | 3 | 2019 | 231 | 0.380 |
Why?
|
| Incisional Hernia | 2 | 2023 | 9 | 0.380 |
Why?
|
| Mandibular Diseases | 1 | 2010 | 45 | 0.380 |
Why?
|
| Breast Implantation | 3 | 2021 | 228 | 0.360 |
Why?
|
| Osteoradionecrosis | 1 | 2010 | 123 | 0.350 |
Why?
|
| Salvage Therapy | 1 | 2018 | 2054 | 0.340 |
Why?
|
| Wound Healing | 4 | 2016 | 815 | 0.340 |
Why?
|
| Pelvis | 1 | 2010 | 362 | 0.330 |
Why?
|
| Biological Products | 2 | 2023 | 274 | 0.330 |
Why?
|
| Reoperation | 6 | 2019 | 1382 | 0.320 |
Why?
|
| Esthetics | 4 | 2020 | 189 | 0.320 |
Why?
|
| Time-to-Treatment | 2 | 2020 | 292 | 0.310 |
Why?
|
| Middle Aged | 41 | 2022 | 86204 | 0.310 |
Why?
|
| Transplantation, Autologous | 5 | 2022 | 1914 | 0.310 |
Why?
|
| Abdominoplasty | 2 | 2018 | 22 | 0.310 |
Why?
|
| Postoperative Care | 1 | 2011 | 739 | 0.290 |
Why?
|
| Rectus Abdominis | 3 | 2011 | 100 | 0.280 |
Why?
|
| Surgical Wound Infection | 6 | 2023 | 450 | 0.270 |
Why?
|
| Radiotherapy, Adjuvant | 3 | 2020 | 2231 | 0.270 |
Why?
|
| Female | 46 | 2021 | 141928 | 0.260 |
Why?
|
| Humans | 56 | 2023 | 261506 | 0.250 |
Why?
|
| Adult | 28 | 2021 | 77950 | 0.250 |
Why?
|
| Propensity Score | 8 | 2018 | 750 | 0.240 |
Why?
|
| Recurrence | 11 | 2023 | 4758 | 0.240 |
Why?
|
| Time Factors | 11 | 2020 | 12926 | 0.220 |
Why?
|
| Chemotherapy, Adjuvant | 3 | 2020 | 3890 | 0.220 |
Why?
|
| Patient Satisfaction | 3 | 2020 | 915 | 0.210 |
Why?
|
| Fibromatosis, Aggressive | 2 | 2013 | 109 | 0.200 |
Why?
|
| Graft Survival | 4 | 2016 | 1062 | 0.200 |
Why?
|
| Logistic Models | 10 | 2016 | 3441 | 0.190 |
Why?
|
| Prophylactic Mastectomy | 1 | 2020 | 35 | 0.190 |
Why?
|
| Aged | 24 | 2021 | 70117 | 0.190 |
Why?
|
| Thoracoplasty | 1 | 2020 | 20 | 0.190 |
Why?
|
| Graft Rejection | 4 | 2016 | 834 | 0.180 |
Why?
|
| Muscle, Skeletal | 3 | 2012 | 1270 | 0.180 |
Why?
|
| Radiation Injuries | 2 | 2018 | 1411 | 0.170 |
Why?
|
| Adipose Tissue | 2 | 2022 | 769 | 0.170 |
Why?
|
| Thoracic Vertebrae | 1 | 2020 | 186 | 0.170 |
Why?
|
| Myocutaneous Flap | 1 | 2019 | 30 | 0.170 |
Why?
|
| Organ Sparing Treatments | 2 | 2019 | 277 | 0.170 |
Why?
|
| Osteotomy | 1 | 2020 | 100 | 0.170 |
Why?
|
| Sarcopenia | 1 | 2020 | 110 | 0.170 |
Why?
|
| Cicatrix | 1 | 2020 | 208 | 0.170 |
Why?
|
| Tissue Expansion Devices | 2 | 2021 | 62 | 0.160 |
Why?
|
| Abdomen | 1 | 2020 | 332 | 0.160 |
Why?
|
| Prospective Studies | 8 | 2022 | 12873 | 0.160 |
Why?
|
| Robotics | 2 | 2012 | 359 | 0.160 |
Why?
|
| Tissue Expansion | 1 | 2018 | 71 | 0.160 |
Why?
|
| Vascular Grafting | 1 | 2018 | 50 | 0.150 |
Why?
|
| Ostomy | 1 | 2016 | 19 | 0.150 |
Why?
|
| Thrombectomy | 1 | 2018 | 158 | 0.150 |
Why?
|
| Male | 26 | 2021 | 123000 | 0.150 |
Why?
|
| Thoracic Neoplasms | 1 | 2020 | 337 | 0.140 |
Why?
|
| Mastectomy, Simple | 1 | 2016 | 58 | 0.140 |
Why?
|
| Elective Surgical Procedures | 1 | 2018 | 250 | 0.140 |
Why?
|
| Fibrinolytic Agents | 1 | 2018 | 324 | 0.130 |
Why?
|
| Spinal Neoplasms | 1 | 2020 | 631 | 0.130 |
Why?
|
| Fasciotomy | 2 | 2013 | 43 | 0.120 |
Why?
|
| Perforator Flap | 1 | 2016 | 93 | 0.120 |
Why?
|
| Body Mass Index | 3 | 2017 | 2203 | 0.120 |
Why?
|
| Cohort Studies | 5 | 2016 | 9244 | 0.120 |
Why?
|
| Risk Assessment | 5 | 2016 | 6869 | 0.120 |
Why?
|
| Wound Infection | 1 | 2014 | 54 | 0.120 |
Why?
|
| Body Dysmorphic Disorders | 1 | 2014 | 31 | 0.120 |
Why?
|
| Patient Readmission | 1 | 2018 | 548 | 0.120 |
Why?
|
| Cattle | 3 | 2021 | 783 | 0.110 |
Why?
|
| Epothilones | 1 | 2013 | 54 | 0.110 |
Why?
|
| Seroma | 3 | 2018 | 79 | 0.110 |
Why?
|
| Body Image | 1 | 2014 | 141 | 0.110 |
Why?
|
| Sternum | 1 | 2013 | 100 | 0.110 |
Why?
|
| Minimally Invasive Surgical Procedures | 2 | 2012 | 500 | 0.110 |
Why?
|
| Nipples | 1 | 2011 | 132 | 0.100 |
Why?
|
| Laparotomy | 1 | 2012 | 211 | 0.100 |
Why?
|
| Incidence | 3 | 2023 | 5673 | 0.100 |
Why?
|
| Prosthesis-Related Infections | 1 | 2013 | 232 | 0.090 |
Why?
|
| Pharyngectomy | 1 | 2010 | 44 | 0.090 |
Why?
|
| Bone Transplantation | 1 | 2010 | 134 | 0.090 |
Why?
|
| Cadaver | 3 | 2018 | 237 | 0.090 |
Why?
|
| Databases, Factual | 2 | 2016 | 2218 | 0.090 |
Why?
|
| Primary Prevention | 1 | 2011 | 255 | 0.090 |
Why?
|
| Young Adult | 6 | 2019 | 21445 | 0.090 |
Why?
|
| Proportional Hazards Models | 5 | 2016 | 4988 | 0.090 |
Why?
|
| Quality of Life | 3 | 2015 | 4532 | 0.090 |
Why?
|
| Radiotherapy | 1 | 2016 | 1824 | 0.080 |
Why?
|
| Thigh | 1 | 2010 | 172 | 0.080 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2015 | 1216 | 0.080 |
Why?
|
| Laryngectomy | 1 | 2010 | 242 | 0.080 |
Why?
|
| Catheterization, Peripheral | 1 | 2010 | 158 | 0.080 |
Why?
|
| Colorectal Neoplasms | 1 | 2023 | 3578 | 0.080 |
Why?
|
| Aged, 80 and over | 6 | 2016 | 29902 | 0.080 |
Why?
|
| Radiotherapy Dosage | 2 | 2016 | 3842 | 0.080 |
Why?
|
| Risk Factors | 4 | 2023 | 17523 | 0.070 |
Why?
|
| Multivariate Analysis | 4 | 2016 | 4298 | 0.070 |
Why?
|
| Head and Neck Neoplasms | 2 | 2014 | 3976 | 0.070 |
Why?
|
| Obesity | 2 | 2017 | 2884 | 0.070 |
Why?
|
| Liver Neoplasms | 1 | 2023 | 4557 | 0.070 |
Why?
|
| Neoadjuvant Therapy | 1 | 2019 | 4975 | 0.070 |
Why?
|
| Neoplasm Staging | 4 | 2016 | 13658 | 0.070 |
Why?
|
| Brachytherapy | 1 | 2010 | 977 | 0.060 |
Why?
|
| Neoplasm Invasiveness | 1 | 2011 | 3981 | 0.060 |
Why?
|
| Neoplasm Recurrence, Local | 5 | 2023 | 10035 | 0.060 |
Why?
|
| Swine | 2 | 2020 | 1541 | 0.060 |
Why?
|
| Centrifugation | 1 | 2021 | 66 | 0.050 |
Why?
|
| Time and Motion Studies | 1 | 2021 | 43 | 0.050 |
Why?
|
| Filtration | 1 | 2021 | 92 | 0.050 |
Why?
|
| Smoking | 1 | 2010 | 2440 | 0.050 |
Why?
|
| Bone Neoplasms | 1 | 2013 | 2576 | 0.050 |
Why?
|
| Bioprosthesis | 2 | 2012 | 167 | 0.050 |
Why?
|
| Sarcoma | 1 | 2010 | 1725 | 0.050 |
Why?
|
| Allografts | 1 | 2021 | 650 | 0.040 |
Why?
|
| Heterografts | 1 | 2021 | 733 | 0.040 |
Why?
|
| Freeze Drying | 1 | 2018 | 30 | 0.040 |
Why?
|
| Combined Modality Therapy | 3 | 2019 | 8865 | 0.040 |
Why?
|
| Abdominal Abscess | 1 | 2017 | 26 | 0.040 |
Why?
|
| Age Factors | 2 | 2016 | 5377 | 0.040 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2019 | 15862 | 0.040 |
Why?
|
| Hepatectomy | 1 | 2023 | 1011 | 0.040 |
Why?
|
| Hernia | 1 | 2016 | 46 | 0.040 |
Why?
|
| Perioperative Care | 1 | 2020 | 451 | 0.030 |
Why?
|
| Survival Analysis | 2 | 2020 | 9180 | 0.030 |
Why?
|
| Hematoma | 1 | 2016 | 160 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2016 | 6207 | 0.030 |
Why?
|
| Length of Stay | 2 | 2013 | 1900 | 0.030 |
Why?
|
| Treatment Failure | 1 | 2018 | 1391 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2010 | 7551 | 0.030 |
Why?
|
| Margins of Excision | 1 | 2016 | 285 | 0.030 |
Why?
|
| Postoperative Period | 1 | 2016 | 665 | 0.030 |
Why?
|
| Prosthesis Design | 1 | 2016 | 749 | 0.030 |
Why?
|
| Statistics, Nonparametric | 1 | 2016 | 980 | 0.030 |
Why?
|
| Breast | 1 | 2020 | 1344 | 0.030 |
Why?
|
| Poisson Distribution | 1 | 2013 | 91 | 0.030 |
Why?
|
| Operative Time | 1 | 2013 | 217 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 2015 | 1323 | 0.030 |
Why?
|
| Academic Medical Centers | 1 | 2015 | 672 | 0.030 |
Why?
|
| Prognosis | 2 | 2020 | 21713 | 0.030 |
Why?
|
| Disease-Free Survival | 2 | 2016 | 10001 | 0.030 |
Why?
|
| Secondary Prevention | 1 | 2013 | 329 | 0.030 |
Why?
|
| Sex Factors | 1 | 2016 | 2139 | 0.020 |
Why?
|
| Speech Intelligibility | 1 | 2010 | 40 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2015 | 2316 | 0.020 |
Why?
|
| Intraoperative Complications | 1 | 2013 | 301 | 0.020 |
Why?
|
| Neoplasm, Residual | 1 | 2016 | 1656 | 0.020 |
Why?
|
| Neoplasms | 1 | 2016 | 15193 | 0.020 |
Why?
|
| Risk Reduction Behavior | 1 | 2011 | 227 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2013 | 1546 | 0.020 |
Why?
|
| Animals | 3 | 2021 | 59536 | 0.020 |
Why?
|
| Pharynx | 1 | 2010 | 153 | 0.020 |
Why?
|
| Endoscopy | 1 | 2012 | 479 | 0.020 |
Why?
|
| Deglutition | 1 | 2010 | 171 | 0.020 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 2010 | 388 | 0.020 |
Why?
|
| Hemangiosarcoma | 1 | 2010 | 234 | 0.020 |
Why?
|
| Equipment Design | 1 | 2010 | 1204 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2012 | 2292 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2016 | 6100 | 0.020 |
Why?
|
| Esophagus | 1 | 2010 | 553 | 0.020 |
Why?
|
| Laryngeal Neoplasms | 1 | 2010 | 518 | 0.020 |
Why?
|
| Patient Care Team | 1 | 2011 | 795 | 0.020 |
Why?
|
| Mass Screening | 1 | 2014 | 1509 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2015 | 4320 | 0.020 |
Why?
|
| Chemoradiotherapy | 1 | 2013 | 1946 | 0.010 |
Why?
|
| Surveys and Questionnaires | 1 | 2015 | 5687 | 0.010 |
Why?
|
| Survival Rate | 1 | 2016 | 12221 | 0.010 |
Why?
|
| Neoplasms, Second Primary | 1 | 2010 | 1350 | 0.010 |
Why?
|
| Adolescent | 2 | 2014 | 31252 | 0.010 |
Why?
|
| Texas | 1 | 2012 | 6311 | 0.010 |
Why?
|
| United States | 1 | 2015 | 15433 | 0.010 |
Why?
|